Multiple endocrine neoplasia type 2 screening

Multiple endocrine neoplasia type 2 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple endocrine neoplasia type 2 from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
Diagnostic Criteria
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Multiple endocrine neoplasia type 2 screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple endocrine neoplasia type 2 screening
CDC on Multiple endocrine neoplasia type 2 screening
Multiple endocrine neoplasia type 2 screening in the news
Blogs on Multiple endocrine neoplasia type 2 screening
Directions to Hospitals Treating Multiple endocrine neoplasia type 2
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

According to the [guideline name], screening for multiple endocrine neoplasia type 2 by RET gene testing is recommended for children with increased risk of Multiple endocrine neoplasia type 2 with increased risk of Multiple endocrine neoplasia type 2.

Screening

• RET gene testing for children with increased risk of Multiple endocrine neoplasia type 2.
• Ionized calcium level yearly for MEN 2A
• Parathyroid hormone level yearly for MEN 2A
• Catacholamines, epinephrine and norepinephrine yearly for MEN 2A and MEN 2B
• Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years